ArticleClinical case reports2025
From Treatment to Toxicity: Metronidazole-Induced Encephalopathy in a 79-Year-Old Woman.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Treatment to Toxicity: Metronidazole-Induced Encephalopathy in a 79-Year-Old Woman.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metronidazole is a commonly used antibiotic effective against anaerobic bacterial and protozoal infections. While generally well tolerated, it is associated with potential neurotoxic effects, including metronidazole-induced encephalopathy (MIE), especially in elderly patients or those with hepatic impairment. We report the case of a 79-year-old woman with a significant medical history who developed neurological symptoms following metronidazole treatment. Initially treated with broad-spectrum antibiotics, she showed limited response, prompting the addition of metronidazole to address suspected amebic infections alongside ongoing therapy with meropenem. Although effective in reducing the abscess size from 12 to 5 cm, the patient subsequently experienced altered mental status and cognitive decline. MRI findings were consistent with MIE. Upon discontinuation of metronidazole, the patient demonstrated notable recovery in cognitive function, confirming the diagnosis and emphasizing the importance of recognizing MIE in at-risk populations. This case underscores the need for careful monitoring and early recognition of neurological complications associated with metronidazole therapy, particularly in older patients or those with comorbidities. Increased awareness among healthcare providers is essential to optimize patient outcomes and prevent unnecessary suffering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.